Diabetes, Obesity and Metabolism, 25(6), 1758-1768. Wiley-Blackwell van der Aart-van der Beek, A B, Apperloo, E, Jongs, N, Rouw, D B, Sjöström, C D, Friedli, I, Johansson, L, van Raalte, D H, Hoogenberg, K & Heerspink, H J L 2023, ' Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes : A randomized cross-over clinical study ', Diabetes, Obesity and Metabolism, vol. 25, no. 6, pp. 1758-1768 . https://doi.org/10.1111/dom.15033
Wheeler, D C, Jongs, N, Stefansson, B, Chertow, G M, Greene, T, Hou, F F, Langkilde, A M, McMurray, J J, Rossing, P, Nowicki, M, Wittmann, I, Correa-Rotter, R, Sjostrom, C D, Toto, R D, Heerspink, H J L & DAPA-CKD Trial Comm Investigators 2022, ' Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis : a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial ', Nephrology Dialysis Transplantation, vol. 37, no. 9, pp. 1647–1656 . https://doi.org/10.1093/ndt/gfab335